GenSight Biologics Reports Cash Position as of September 30, 2025

Paris, France, Tuesday October 7, 2024, 6:00 pm CEST – GenSight Biologics (“GenSight Biologics” or the “Company“) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of September 30, 2025.

Cash Position and Outlook

GenSight Biologics’ cash and cash equivalents totalled €0.6 million as of September 30, 2025, compared to €0.3 million as of June 30, 2025.

On October 1, 2025, the company received the net proceeds from the fundraising completed on September 26, 2025,  totaling €3.0 million, net of the repayment of €0.7 million principal on the convertible bonds held by Heights Capital. As of October 1, 2025, GenSight Biologics’ cash and cash equivalents totaled €3.6 million.

The company has sufficient net working capital to meet its obligations only until the end of the fourth quarter of 2025. However, the cash runway could extend to the end of May 2026 if a positive regulatory decision occurs before the end of the year.

The Management’s plan and financing strategy presented in the HY 2025 Financial Statement press release issued on September 29, 2025 remains valid.

Share Information

As of October 1, 2025, GenSight Biologics had 174,475,604 outstanding ordinary shares.